Case‐Based Review of Amyloid PET Negative Cases in a Large Memory Clinic: Considerations for Differential Diagnosis

In the era of disease-modifying treatments, amyloid PET will increasingly be used to identify patients appropriate for amyloid-directed treatments, leading to continued diagnostic uncertainty for patients with a negative Alzheimer's disease biomarker, especially in non-specialist settings. This has ethical implications for caring for these patients. Further research is needed to establish reliable biomarkers for other neuropathological diagnoses to reduce diagnostic uncertainty and improve the care for non-Alzheimer's dementia.